Orally Dispersible Tablet of Mesalazine: Formulation and Evaluation

Year : 2025 | Volume : 12 | Issue : 02 | Page : 16 25
    By

    Himanshu Rajendra Nikam,

  • Yogesh B. Rokade,

  1. Student, Department of pharmaceutics, P.S.G.V.P. Mandal’s College of pharmacy, Shahada, Maharashtra, India
  2. Student, Department of pharmaceutics, P.S.G.V.P. Mandal’s College of pharmacy, Shahada, Maharashtra, India

Abstract

Oral disintegrating tablets (ODTs) become increasingly more and more popular, particularly among elderly and paediatric patients who have difficulties with swallowing. The 5-aminosalicylic acid compound oral mesalazine, frequently referred to as mesalamine, is used to treat mild to severe ulcerative colitis and has a high percentage of success in causing and establishing response. Mesalazine has a topical therapeutic action at the location of the suffering colonic mucosa. The medication’s disadvantage is that it is nearly insoluble in water, which results in poor solubility, GI absorption, and bioavailability. Therefore, the goal of this study is to create an oral disintegrating tablet of mesalazine by combining croscormellose (CM) with its kneading mixture and using croscormellose as a super disintegrating agent. The present rsearch has been undertaken with the aim to formulate and evaluate the oral dispersible tablet of mesalazine.

Keywords: Colitis; Ulcerative; Oral dispersible tablet (ODT); Mesalamine (Mesalazine/ 5- Amino salicylic acid); kneading mixture.

[This article belongs to Research & Reviews: A Journal of Drug Formulation, Development and Production ]

How to cite this article:
Himanshu Rajendra Nikam, Yogesh B. Rokade. Orally Dispersible Tablet of Mesalazine: Formulation and Evaluation. Research & Reviews: A Journal of Drug Formulation, Development and Production. 2025; 12(02):16-25.
How to cite this URL:
Himanshu Rajendra Nikam, Yogesh B. Rokade. Orally Dispersible Tablet of Mesalazine: Formulation and Evaluation. Research & Reviews: A Journal of Drug Formulation, Development and Production. 2025; 12(02):16-25. Available from: https://journals.stmjournals.com/rrjodfdp/article=2025/view=208807


References

  1. Shukla D, Chakraborty S, Singh S, Mishra B. Mouth dissolving tablets I: An overview of formunation technology. Sci Pharm., 2009; 77: 309-26.
  2. Sahoo CK, Sahoo TK, Moharana AK. Designing of orodispersible tablet of diethyl carbamazine citrate for the treatment of filariasis. Inter J Appl Biol Pharm Tech. 2011;2:70-
  3. Peppercorn, M A, and Goldman, P, 3’ournal of Pharmacology and Experi-mental Therapeutics, 1972, 181, 555.
  4. Sandberg-Gertzén H, Rydc H, Järnerot G. Absorption and excretion of a single 1 g dose of azodisal sodium in subjects with ileostomy. Scand J Gastroenterol 1983; 18: 107 – 11.
  5. Smart JD., Lectin-mediated drug delivery in the oral cavity. Adv. Drug Deliv. Rev. 2004, 56: 481–489.
  6. Seager H., Drug delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol 1998, 50: 375-382.
  7. Ghosh TK., Pfister WR., Quick dissolving oral dosage forms: Scientific and regulatory considerations from a clinical pharmacology and biopharmaceuticals perspective; In: Drug delivery to the oral cavity: Molecules to market. New York, CRC Press (2005), 337 356.
  8. Brown D., Orally disintegrating tablets: Taste over speed. Drug Deliv Technol 2001, 3: 58-
  9. Ligumsky M, Karmeli F, Sharon P, Zor U, Cohen F, Rachmilewitz D. Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine.Gastroenterology 1981; 81: 444-449 [PMID: 6114012]
  1. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF, Desreumaux P. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 2005; 201: 1205-1215 [PMID: 15824083 DOI: 10.1084/jem.20041948]
  1. Schröder H, Campbell DE. Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther 1972; 13: 539-551 [PMID: 4402886]
  2. Moss AC, Peppercorn MA. The risks and the benefits of mesalazine as a treatment for ulcerative colitis. Expert Opin Drug Saf 2007; 6: 99-107 [PMID: 17367256 DOI: 10.1517/14740338.6.2.99]
  3. Modi A and Tayade P. Enhancement of dissolution profile by solid dispersion (kneading) technique. AAPS Pharm. Sci. Tech. 2006, 7: article 68.
  4. Kushekar BS., Mouth dissolving tablets: A Novel Drug Delivery system. Pharma times .2003; 35.
  5. Shyamala B., Narmada GY., Rapid dissolving tablets: A Novel dosage form. The Indian Pharmacist. 2002, 13(8): 09-12.
  6. Bradoo R., Fast dissolving drug delivery systems. JAMA India. 2001, 4(10): 27-31.
  7. Makino T., Yamada M., Kikuta J., Fast dissolving tablet and its Production. 1993; European Patent, 0553777 A2.
  8. Cirri M., Valleri M., Mura P., Maestrelli F., Ballerini R., Development of fast-dissolving tablets of flurbiprofen-cyclodextrin complexes. Drug Dev. Ind. Pharm., 31(7), 2005; 697-707.

 

Regular Issue Subscription Original Research
Volume 12
Issue 02
Received 29/03/2025
Accepted 21/04/2025
Published 26/04/2025
Publication Time 28 Days
350

Login


My IP

PlumX Metrics